Viridian Therapeutics Prepares for Transformational 2026 [Yahoo! Finance]
Viridian Therapeutics, Inc. (VRDN)
Company Research
Source: Yahoo! Finance
- Topline phase 3 results for subcutaneous elegrobart (VRDN-003) on track for Q1 2026 for REVEAL-1 and Q2 2026 for REVEAL-2 for active and chronic TED, respectively - - IND submitted for half-life extended FcRn-inhibitor, VRDN-008; healthy volunteer (HV) data expected in 2H 2026 - - Unveiling new program targeting thyroid-stimulating hormone receptor (TSHR); IND expected Q4 2026 - - Cash position of approximately $888 million as of October 31, 2025 - - Company expects its current business plans to be funded through profitability - WALTHAM, Mass., January 06, 2026 BUSINESS WIRE )--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for serious and rare diseases, today announces the company's key priorities and anticipated catalysts for 2026. "Following another year of strong execution across our portfolio, we enter 2026 positioned for meaningful value-creation and progr
Show less
Read more
Impact Snapshot
Event Time:
VRDN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VRDN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VRDN alerts
High impacting Viridian Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
VRDN
News
- Viridian Therapeutics (NASDAQ:VRDN) was upgraded by analysts at UBS Group AG to a "strong-buy" rating.MarketBeat
- Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- Viridian Therapeutics (NASDAQ:VRDN) had its price target lowered by analysts at Truist Financial Corporation from $41.00 to $40.00. They now have a "buy" rating on the stock.MarketBeat
- Viridian Therapeutics (NASDAQ:VRDN) is now covered by analysts at UBS Group AG. They set a "buy" rating on the stock.MarketBeat
- Viridian Therapeutics Prepares for Transformational 2026Business Wire
VRDN
Earnings
- 2/27/25 - Beat
VRDN
Sec Filings
- 1/2/26 - Form 4
- 12/31/25 - Form 144
- 11/14/25 - Form SCHEDULE
- VRDN's page on the SEC website